MSD getting closer to USD 40bn acquisition of Seagen, media reports
The two companies are discussing a price of over USD 200 per share and a final agreement by July 28.
by marketwire, translated by catherine brett
US-based pharmaceutical giant MSD is in advanced negotiations concerning the acquisition of Seagen, a biotech firm focusing on oncology, for around USD 40bn, the Wall Street Journal reports after speaking to people close to the matter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Evaxion Biotech's lung cancer candidate ready for clinic
For subscribers
MSD eyeing Seagen acquisition, media reports
For subscribers
